Compare HTOO & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTOO | NXL |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.5M |
| IPO Year | 2020 | 2022 |
| Metric | HTOO | NXL |
|---|---|---|
| Price | $2.15 | $5.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.5K | ★ 100.2K |
| Earning Date | 02-28-2023 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $301,647.00 |
| Revenue This Year | $4,832.46 | $15.52 |
| Revenue Next Year | $81.82 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 78.78 |
| 52 Week Low | $1.80 | $0.22 |
| 52 Week High | $5.74 | $7.69 |
| Indicator | HTOO | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 65.60 |
| Support Level | $1.80 | $4.51 |
| Resistance Level | $2.75 | $7.69 |
| Average True Range (ATR) | 0.20 | 0.60 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 4.42 | 12.26 |
Fusion Fuel Green PLC is a provider of full-service energy engineering and advisory solutions, specializing in green hydrogen and industrial gas applications. It offers a broad portfolio of services, including the design, supply, installation and maintenance of energy systems, as well as the transport and distribution of liquefied petroleum gas. The company serves a diverse customer base spanning commercial buildings, mixed-use developments, heavy industries, and food service sectors. The group currently derives revenue by providing comprehensive solutions for the liquefied petroleum gas (LPG) industry, which includes the supply, installation, and maintenance of LPG systems, as well as transportation and delivery of LPG in both bulk and cylinder formats. It earns majority revenue from UAE.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.